Michael B. Gorin, MD, PhD: Interim TEASE-3 Trial Data in Sta

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

Related Keywords

United States , American , Michaelb Gorin , , Alkeus Pharmaceuticals , American Academy Of Ophthalmology Meeting , David Geffen School Of Medicine , David Geffen School , Annual American Academy ,